Biotech Values

[DewDiligence]

[OT] Merck and Schering-Plough:

>> [From the CBS article]: Still, Merck does have its share of defenders, who highlight the potential of a new combination cholesterol therapy. Merck and partner Schering-Plough recently applied for U.S. clearance to market their cholesterol medications, Zetia and Zocor, in a single pill. The combination is expected to win Food and Drug Administration approval next year. <<

I used to be a big believer in the potential for Zetia and the Zocor/Zetia combo pill, but I have recently changed my view and now think these products will fall short of many investors’ expectations. FWIW